October 2011 Diabetes

Pharmacists must be aware of potentially serious adverse reactions in patients receiving angiotensin- converting enzyme therapy, particularly with the concurrent use of dipeptidly peptidase IV inhibitors.

The metabolic chain reaction that precedes diabetic ketoacidosis can occur rapidly and this potentially life-threatening condition requires swift recognition and treatment.

The management of type 1 and type 2 diabetes is a booming area of research and development, and the pipeline contains many innovative drugs and dosage forms.

Individuals with diabetes should not overlook preventive skin care as part of their diabetes management routine.

When lifestyle modifications and OTC treatment are not sufficient for the relief of chronic constipation, there is a prescription option available.